HC Wainwright & Co. maintains Agios Pharmaceuticals at Buy, raises price target to $62 from $55
HC Wainwright & Co. kept its Buy rating on Agios Pharmaceuticals and raised its price target to $62 from $55, citing a 12.7% increase. This implies an upside of 119.3% from the Nov 5 close of $28.27.
How this was made

The 30-second read
Why it matters
The price target increase signals confidence in Agios' pipeline, potentially prompting short-term buying.
Market read
Analyst price target upgrades are modest catalysts that can generate short-term price moves in small-cap biotech stocks.
What to watch
Potential dilution from future financing or regulatory setbacks.
Background
HC Wainwright is a mid-size research firm; its upgrades can move small-cap biotech stocks.
Ticker impact
HC Wainwright raised Agios Pharmaceuticals' price target to $62 from $55, indicating a bullish outlook.
likely upward pressure as investors price in the higher target
The new target represents a 12.7% increase and implies a 119% upside from the current price, which can attract buying interest.
Market effects
May lift sentiment in the biotech sector as analysts raise targets.
Limited to US biotech equities.
Low, confined to Agios and peers.
Counterpoint
The target raise could be premature if upcoming trial data disappoints.
Key entities
- Research FirmHC Wainwright & Co.
Provided the upgraded rating and price target.
- Biotech CompanyAgios Pharmaceuticals
Subject of the analyst upgrade.


